ストックスクリーナーアプリを入手
34.96
2.53%
-1.04
前日終値:
$36.00
開ける：
$36.04
24時間の取引高:
1.05M
Relative Volume:
1.31
時価総額：
$1.88B
収益：
-
当期純損益:
$-119.95M
株価収益率:
-17.37
EPS:
-2.0123
ネットキャッシュフロー:
$-95.28M
1週間 パフォーマンス:
+0.14%
1か月 パフォーマンス:
+25.37%
6か月 パフォーマンス:
+180.27%
1年 パフォーマンス:
+226.72%
1日の値動き範囲:
$34.00
$36.96
1週間の範囲:
$33.20
$36.96
52週間の値動き範囲:
$6.42
$36.96
Tyra Biosciences Inc Stock (TYRA) Company Profile
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
34.83 | 1.94B | 0 | -119.95M | -95.28M | -2.0123 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.07 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.87 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.79 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.94 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.46 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-02-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-21 | 再開されました | Piper Sandler | Overweight |
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-10-18 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-08-15 | 開始されました | Piper Sandler | Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-30 | 開始されました | Wedbush | Outperform |
| 2023-02-03 | 開始されました | Oppenheimer | Outperform |
| 2022-06-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-11-08 | ダウングレード | Jefferies | Buy → Hold |
| 2021-10-11 | 開始されました | BofA Securities | Buy |
| 2021-10-11 | 開始されました | Cowen | Outperform |
| 2021-10-11 | 開始されました | Jefferies | Buy |
すべてを表示
Tyra Biosciences Inc (TYRA) 最新ニュース
Tyra Biosciences stock hits all-time high at 36.69 USD - Investing.com
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines - Traders Union
Tyra Biosciences (NASDAQ:TYRA) Sets New 12-Month HighHere's What Happened - MarketBeat
Trading the Move, Not the Narrative: (TYRA) Edition - Stock Traders Daily
Assessing Tyra Biosciences (TYRA) Valuation After Wider Full Year Loss And Earnings Update - Sahm
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Technicals: Is Tyra Biosciences Incs ROE strong enoughQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Update Recap: Is Tyra Biosciences Inc a strong candidate for buy and holdJuly 2025 Macro Moves & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress - Sahm
Is Tyra Biosciences Inc stock undervalued right nowJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
HC Wainwright Issues Optimistic Forecast for TYRA Earnings - Defense World
Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com Nigeria
HC Wainwright Boosts Earnings Estimates for Tyra Biosciences - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat
Growth Stocks To Keep An Eye On – March 3rd - Defense World
Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com Australia
Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Nigeria
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget
Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com
Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView
Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView
Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
TYRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tyra Biosciences Q4 Loss Widens - marketscreener.com
Tyra Biosciences 10-K: Net loss $119.95M, EPS $(2.01) - TradingView
Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan
Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - simplywall.st
Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
TYRA Should I Buy - Intellectia AI
Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
(TYRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
TYRA: Phase II trials for dabogratinib target NMIBC, UTUC, and achondroplasia, with key data due this year - TradingView
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
Tyra Biosciences (TYRA) Price Target Increased by 14.97% to 48.96 - Nasdaq
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Tyra Biosciences stock hits all-time high at 34.0 USD - Investing.com India
Tyra Biosciences Inc (TYRA) 財務データ
収益
当期純利益
現金流量
EPS
Tyra Biosciences Inc (TYRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bensen Daniel | Chief Discovery Officer |
Feb 12 '26 |
Sale |
32.87 |
8,000 |
262,965 |
146,981 |
0.41%
大文字化:
|
ボリューム (24 時間):